GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives

GT Biopharma, Inc.

(the “Company”) (NASDAQ:
GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager TriKE^®^ platform, today provided an update on its newly implemented AI-based technological initiatives and improved pipeline discovery efficiencies, which are expected to lead to additional development candidates advancing into pre-IND development in 2027.
"We have seen a marked acceleration in our discovery productivity following recent initiatives implementing AI-based technologies, which have been adapted to improve our drug engineering capabilities," said Michael Breen, Executive Chairman and Chief Executive Officer.
...
**Implementation of AI-based technology for GT Biopharma’s Discovery Pipeline **
- AI-guided sequence and structural analyses are used to identify *de novo * candidate tumor-targeting engagers and multi-domain proteins with favorable binding, stability, and developability profiles, enabling early prioritization of molecules most likely to demonstrate translation success beyond discovery.
- These tools further inform rational engineering by optimizing domain orientation, linker design, and spatial architecture to enhance binding, support productive immune synapse formation, and minimize structural liabilities that can impair potency, manufacturability, or consistency.
- In downstream applications, AI-based structural modeling is applied to predict surface exposure, steric compatibility, and assay performance, guiding construct refinement prior to resource-intensive in vitro and in vivo studies.